HUA MEDICINE-B (02552) surged over 3%, reaching HK$3.25 by the time of writing, with a trading volume of HK$3.303 million.

On December 9, the company announced the successful first dosing in its U.S. multiple-ascending-dose (MAD) Ib trial for its second-generation glucokinase activator (GKA), HMS1005 (formerly HM-002-1005). This randomized, double-blind, placebo-controlled study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in patients with type 2 diabetes (T2D).

The trial will further investigate HMS1005's mechanism and efficacy by assessing PD markers (including blood glucose, insulin, C-peptide, GLP-1, and glucagon) under fasting and fed conditions, alongside continuous glucose monitoring (CGM) to track glycemic fluctuations.

HMS1005 is an improved molecular entity designed as a once-daily extended-release formulation, enhancing patient convenience and intestinal retention to better address GLP-1 deficiency. The company previously validated its feasibility for once-daily oral treatment in T2D and obesity patients through a completed single-ascending-dose study.

Following the MAD Ib trial's completion, HUA MEDICINE-B plans to seek global partners for HMS1005's development.